Cumberland Pharmaceuticals (CPIX)
Develops ifetroban for rare-disease complications while retaining a life-sciences venture interest.
Something off on this page? Send us feedback.
Develops ifetroban across clinical programs for Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis and idiopathic pulmonary fibrosis. Following the sale of its branded pharmaceutical portfolio to Apotex, it retains product candidates and a majority interest in Cumberland Emerging Technologies.
Built branded prescription medicines through internal development, licensing and acquisitions, including Acetadote, Kristalose, Vibativ, Sancuso and Talicia. That commercial portfolio was sold to Apotex in July 2026, shifting the active focus away from those medicines.
Current development centers on ifetroban, a thromboxane antagonist in clinical programs for cardiomyopathy associated with Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis. The retained pipeline makes clinical development and regulatory progress central to the operating model.
Cumberland also retains a majority interest in Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee supporting early-stage life-sciences programs and companies.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.9M · Total debt $4.7M · Total assets $62.9M · Shareholders' equity $17.4M
- Revenue
- $166.5K
- Operating income
- −$3.2M
- Net income
- −$4.1M
To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 3, 2026 | Jul 23 | $1.50 |
| Institutions34 holders · as of Mar 31, 2026 | 18.43% | 2.76M shares | |
| Insiders7 holders · as of Mar 20, 2026 | 41.20% | 6.17M shares | |
| Otherremainder | 40.37% | 6.05M shares |
14.98M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
A. J. KazimiInsiderdirector, 10 percent owner, officer: Chairman and CEO | 38.01% | 5.70M | Form 4filed Mar 18, 2026 ↗ |
Ikarian Capital, LLCInstitution | 3.69% | 553,153 | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 3.14% | 470,696 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 2.41% | 361,759 | 13Fas of Mar 31, 2026 |
Kenneth KrogulskiInsiderdirector | 2.02% | 302,338 | Form 4filed Mar 20, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 1, 2025 | Kenneth Krogulski | director | +68 | $3.44 |
| Aug 4, 2025 | Kenneth Krogulski | director | +68 | $4.01 |
| Aug 5, 2025 | Kenneth Krogulski | director | +68 | $3.92 |
| Aug 6, 2025 | Kenneth Krogulski | director | +68 | $3.34 |
| Aug 7, 2025 | Kenneth Krogulski | director | +68 | $3.14 |
- Sarepta Therapeutics
Rare-disease leader with an approved Duchenne gene therapy
- United Therapeutics
Late-stage inhaled treprostinil program for idiopathic pulmonary fibrosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cumberland Pharmaceuticals | $6.53 | −0.46% | $97.7M | — | — | 3.1 | −98.5% |
| Sarepta Therapeutics | $23.15 | −0.26% | $2.45B | — | 28.9 | 1.2 | −34.3% |
| United Therapeutics | $480.00 | −2.43% | $20.88B | 17.6 | 18.9 | 6.6 | −1.9% |
| Median | 17.6 | 23.9 | 3.9 | −18.1% |